Eli Lilly Tops Estimates, Raises Forecast on GLP-1 Drug Sales
Eli Lilly and Company reported stronger-than-expected quarterly results on Wednesday, driven by robust demand for its blockbuster GLP-1 drugs for diabetes and obesity.
The pharmaceutical giant also raised its full-year revenue forecast, reflecting confidence in sustained growth fueled by these high-demand treatments.
Sales of its diabetes drug Mounjaro surged 91 per cent year-on-year to $9.94 billion, significantly outperforming analysts’ expectations.
The drug has rapidly gained traction in global markets, benefiting from increasing diagnosis rates and wider adoption among patients seeking more effective glucose control therapies.
Meanwhile, obesity treatment Zepbound generated $4.93 billion in revenue during the quarter, exceeding market forecasts of $4.73 billion.
The strong performance underscores the growing demand for weight-loss medications, as obesity rates continue to rise worldwide and healthcare providers increasingly prescribe advanced GLP-1 therapies.
Also Read: US to Review Closed AI Systems before Rollout under Trump Plan
The company’s upbeat results highlight the commercial success of its incretin-based portfolio, which has become a key growth driver. Eli Lilly has been expanding manufacturing capacity and investing heavily in research and development to meet surging demand and maintain its competitive edge in the fast-growing metabolic disease segment.
Also Read: Australia Warns Gas-Powered Data Centres May Breach Rules
In addition to strong product sales, the company’s revised revenue outlook signals optimism about continued momentum in the coming quarters. Analysts note that the sustained popularity of GLP-1 drugs, coupled with ongoing innovation, positions Eli Lilly favorably against competitors in the obesity and diabetes treatment markets.
Also Read: Jeff Dean Starts Discovery Loop to Accelerate AI-Driven Science
Looking ahead, the company is expected to focus on scaling production, expanding global access, and advancing its pipeline of next-generation therapies. With demand for weight-loss and diabetes drugs showing no signs of slowing, Eli Lilly appears well-positioned to sustain its growth trajectory and deliver strong financial performance through the remainder of the year.